TY  - JOUR
T1  - Cyclosporine in psoriasis treatment: Inhibition of keratinocyte cell-cycle progression in g1 independent of effects on transforming growth factor a/epidermal growth factor receptor pathways
AU  - Khandke L, Krane JF, Ashinoff R, et al
Y1  - 1991/08/01
N1  - 10.1001/archderm.1991.01680070072008
JO  - Archives of Dermatology
SP  - 1172
EP  - 1179
VL  - 127
IS  - 8
N2  - • Cyclosporine, an immunosuppressive drug, is effective in the treatment of recalcitrant psoriasis. Previous work suggested that keratinocyte hyperproliferation and inflammation are linked in psoriasis and that immune mechanisms participate in the pathogenesis of psoriasis. Transforming growth factor (TGF) α may be an important regulatory factor of epidermal growth as overproduction of TGF-α is associated with epidermal hyperplasia in psoriatic plaques and epidermal growth factor receptors are overexpressed in psoriatic epithelium. In this study, the effects of cyclosporine on cultured human keratinocytes were examined. Cyclosporine specifically inhibited keratinocyte cell-cycle progression in the G1 phase without causing keratinocytes to terminally differentiate. Cyclosporine did not decrease the expression of TGF-α or epidermal growth factor receptors. These results suggest that the effects of cyclosporine on psoriatic skin are unrelated to direct effects on autocrine growth regulation of keratinocytes via TGF-α production or of epidermal growth factor receptor modulation.(Arch Dermatol. 1991;127:1172-1179)
SN  - 0003-987X
M3  - doi: 10.1001/archderm.1991.01680070072008
UR  - http://dx.doi.org/10.1001/archderm.1991.01680070072008
ER  -